The history of Viagra presents a challenging picture for shareholders. While the initial launch generated significant gains, the lapse of its intellectual property protection opened the avenue to cheaper competitors, dramatically eroding sales. This poses a particular dilemma for pharmaceutical companies depending on related blockbuster medications

The history of Viagra, and its parent company copyright, presents a complex case study for investors. At first a blockbuster drug, producing billions in income, its patent expiration created a wave of generic competition , significantly eroding its dominance. While certain firms may try to capitalize on related treatments , the current landscape de